ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meeting Abstracts
    • All Meetings
    • PRSYM 2026
    • ACR Convergence 2025
    • Download Abstract Supplements
  • Keyword Index
  • Search
  • My Favorites
    • View and print all favorites
    • Clear all favorites

Abstract Number: 1615

Assessment of a Cognitive Impairment Measure in Systemic Lupus Erythematosus

Nicole Davidson1, Alexa Meara2, Holly Steigelman3, Songzhu Zhao4, Guy Brock5, Wael Jarjour6, Brad H. Rovin7, Samir parikh4, Hareth M. Madhoun8, Lee Hebert9, Isabelle Ayoub4 and Stacy P. Ardoin10, 1The Ohio State University, The Ohio State University, Columbus, OH, 2Internal Medicine/Rheumatology, The Ohio State University Wexner Medical Center, Columbus, OH, 3The Ohio State University Wexner Medical Center, Columbus, OH, 4The Ohio State University, Columbus, OH, 5Department of Biomedical Informatics and Center for Biostatistics, The Ohio State University Wexner Medical Center, Columbus, OH, 6Department of Rheumatology/Medicine, Ohio State University, Columbus, OH, 7Ohio State University Medical Center, Columbus, OH, 8Rheumatology/Immunology, The Ohio State University Wexner Medical Center, Columbus, OH, 9Medicine, Ohio State University Medical Center, Columbus, OH, 10Pediatric & Adult Rheumatology, The Ohio State University Wexner Medical Center, Columbus, OH

Meeting: ACR/ARHP Annual Meeting 2017

Date of first publication: September 18, 2017

Keywords: Co-morbidities, measure and systemic lupus erythematosus (SLE)

  • Tweet
  • Email a link to a friend (Opens in new window) Email
  • Print (Opens in new window) Print
Session Information

Date: Monday, November 6, 2017

Title: Systemic Lupus Erythematosus – Clinical Aspects and Treatment Poster II: Damage and Comorbidities

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: : Systemic lupus erythematosus (SLE) is a multisystem autoimmune disease which can impact the central nervous system in multiple ways, including development of cognitive dysfunction. Cognitive dysfunction is commonly reported in SLE and difficult to detect. Currently used diagnostic methods including neurocognitive testing batteries are time consuming, costly and challenging to implement in clinic. This project used the Self-Administered Gerocognitive Exam (SAGE) screening test for cognitive impairment, a simple patient-completed paper test, validated for dementia, diabetes and other diseases but not SLE

Methods:

The patient population included 118 patients participating in The Ohio State University Lupus, Vasculitis and Glomerulonephritis Registry. All subjects provided informed consent, completed the SAGE instrument and supplied demographic and medical history information. Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) and Systemic Lupus International Collaborative Clinics Damage Index (SLICC-DI) were completed on all subjects. SAGE instruments, scored by a trained individual, were grouped into two categories: normal (SAGE score > 16) and abnormal (SAGE score ≤ 16). Univariate analysis was performed to assess the relationship between normal and abnormal SAGE scores and several clinical variables. Variables with p < 0.15 from the univariate analysis were initially included in multivariable logistic regression modeling. Variables with p>0.05 were subsequently removed sequentially from multivariate model using the backward selection strategy.

Results: Of the 118 subjects in this study, 97 scored in the normal range (>16) and 21 scored in the abnormal range (≤ 16). Race, ethnicity, education level and household income were significantly associated by univariate analysis with normal versus abnormal SAGE scores at the p<0.15 level were initially included in the multivariable model (Table 1). Abnormal SAGE scores were associated with higher overall SLICC DI scores but not with a neuropsychiatric-specific SLICC DI score. In multivariable analysis there was an independent association between abnormal SAGE score and higher SLICC DI score (odds ratio (OR) = 1.44, 95%CI 1.01-1.11, p-value=0.03), Hispanic ethnicity (OR=43.4, 95%CI 3.1-601, p-value=0.005) and lower household income (OR=11.9 for ≤$15,000 vs >$50,000, 95%CI 2.45-57. 8, p-value=0.002).

Conclusion:

Study results show a significant independent relationship between neurocognitive impairment as measured by SAGE score and higher lupus related damage as measured by SLICC DI scores. Abnormal SAGE scores were associated with lower household income and Hispanic ethnicity, which may suggest language barriers and a need for a Spanish version of the instrument. Finally, the SAGE was feasible to measure in the clinic setting. Further validation studies in SLE are needed.

Table 1 Association of clinical variables with normal and abnormal SAGE score

Normal SAGE score

(N=97)

Abnormal SAGE score

(N=21)

P-value1

N (%)

N (%)

Gender

Female

86 (88.66)

20 (95.24)

Male

11 (11.34)

1 (4.76)

0.6904

Race

White

65 (67.01)

7 (33.33)

Black

25 (25.77)

12 (57.14)

Other

7 (7.22)

2 (9.52)

0.0126

Ethnicity

Hispanic or Latino

2 (2.06)

3 (14.29)

Not Hispanic or Latino

95 (97.94)

18 (85.71)

0.0388

Household Income

up to $15,000

11 (13.41)

10 (58.82)

$15,001 – $50,000

35 (42.68)

4 (23.53)

> $50,000

36 (43.90)

3 (17.65)

0.0002

Education

≤High school/GED

17 (18.09)

9 (42.86)

College < four years

22 (23.40)

4 (19.05)

College ≥4 years

48 (51.06)

7 (33.33)

Other

7 (7.45)

1 (4.76)

0.1236

Antidepressant

Yes

30 (30.93)

6 (28.57)

No

67 (69.07)

15 (71.43)

0.8316

Hydroxychloroquine

Yes

85 (87.63)

18 (85.71)

No

12 (12.37)

3 (14.29)

0.7294

Immunosuppressant

Yes

60 (61.86)

15 (71.43)

No

37 (38.14)

6 (28.57)

0.4086

Narcotic

Yes

28 (28.87)

7 (33.33)

No

69 (71.13)

14 (66.67)

0.6845

Other Neuroactive

Yes

34 (35.05)

9 (42.86)

No

63 (64.95)

12 (57.14)

0.5004

Prednisone

Yes

66 (68.04)

15 (71.43)

No

31 (31.96)

6 (28.57)

0.7616

Feel Sad/Depressed

Yes

12 (12.37)

3 (14.29)

Occasionally

31 (31.96)

6 (28.57)

No

54 (55.67)

12 (57.14)

0.9419

SLICC DI Sore

0

41 (44.09)

5 (23.81)

1 or higher

52 (55.91)

16 (76.19)

0.0871

Mean (SD)

Mean (SD)

P-value²

Age (years)

41.40 (12.82)

43.67 (12.50)

0.4626

Median (Min, Max)

Median (Min, Max)

P-value3

Prednisone Dose (mg)

5 (0, 60)

5 (0, 40)

0.6919

SLEDAI Score

2 (0, 31)

2 (0, 16)

0.8680

SLICC DI Score

1 (0, 9)

2 (0, 7)

0.0465

SLEDAI: Systemic lupus erythematosis disease activity index; SLICC DI: Systemic Lupus International Collaborative Clinics Damage Index; SAGE: Self-Administered Gerocognitive Exam; GED: General Educational Development.

¹ P-value from chi-squared test or Fisher’s exact test

² P-value from t-test

³ P-value from Wilcoxon-Mann-Whitney test


Disclosure: N. Davidson, None; A. Meara, None; H. Steigelman, None; S. Zhao, None; G. Brock, None; W. Jarjour, None; B. H. Rovin, None; S. parikh, None; H. M. Madhoun, None; L. Hebert, None; I. Ayoub, None; S. P. Ardoin, not applicable, 9.

To cite this abstract in AMA style:

Davidson N, Meara A, Steigelman H, Zhao S, Brock G, Jarjour W, Rovin BH, parikh S, Madhoun HM, Hebert L, Ayoub I, Ardoin SP. Assessment of a Cognitive Impairment Measure in Systemic Lupus Erythematosus [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/assessment-of-a-cognitive-impairment-measure-in-systemic-lupus-erythematosus/. Accessed .
  • Tweet
  • Email a link to a friend (Opens in new window) Email
  • Print (Opens in new window) Print

« Back to ACR/ARHP Annual Meeting 2017

ACR Meeting Abstracts - https://acrabstracts.org/abstract/assessment-of-a-cognitive-impairment-measure-in-systemic-lupus-erythematosus/

Advanced Search

My Favorites

Save and print abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract (must have cookies enabled in browser). See saved favorites.

Abstract Policies

  • ACR Convergence Abstract Embargo Policies
  • ACR Convergence Abstract Permissions & Reprints
  • PRSYM Abstract Policies

ACR Convergence. Where Rheumatology Meets

ACR Convergence 2026

Join us November 6-11 in Orlando, Florida.
See Registration Information

  • Contact ACR
  • Privacy Policy
  • ACR Policies
  • Cookie Preferences

© Copyright 2026 American College of Rheumatology